Ensysce Biosciences (ENSC) Liabilities and Shareholders Equity (2017 - 2025)

Ensysce Biosciences (ENSC) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $7.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 33.15% year-over-year to $7.5 million; the TTM figure through Dec 2025 stood at $20.8 million (down 8.9% YoY), while the FY2025 annual figure was $7.5 million, up 33.15% from the prior year.
• Liabilities and Shareholders Equity improved to $7.5 million in Q4 2025 per ENSC's latest filing, from $3.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $16.4 million in Q4 2021 and bottomed at $1.1 million in Q2 2021.
• Historically, Liabilities and Shareholders Equity has averaged $6.3 million across 5 years, with a median of $5.6 million in 2024.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 4566.58% in 2021 and fell as far as 92.03% in 2021.
• Ensysce Biosciences' Liabilities and Shareholders Equity stood at $16.4 million in 2021, then sank by 64.15% to $5.9 million in 2022, then slumped by 53.98% to $2.7 million in 2023, then jumped by 106.69% to $5.6 million in 2024, then surged by 33.15% to $7.5 million in 2025.
• Business Quant data shows ENSC's Liabilities and Shareholders Equity at $7.5 million in Q4 2025, $3.2 million in Q3 2025, and $5.6 million in Q2 2025.